R-pharm Us Llc Drug Patent Portfolio
R-pharm Us Llc owns 1 orange book drug protected by 12 US patents Given below is the list of R-pharm Us Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7312237 | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases | 21 Feb, 2025 | Active |
| US7312237 | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases | 21 Aug, 2024 | Expired |
| USRE41393 | Treatment of refractory tumors using epothilone derivatives | 08 Aug, 2022 | Expired |
| US6670384 | Methods of administering epothilone analogs for the treatment of cancer | 23 Jul, 2022 | Expired |
| US7022330 | Parenteral formulation for epothilone analogs | 23 Jul, 2022 | Expired |
| USRE41393 | Treatment of refractory tumors using epothilone derivatives | 08 Feb, 2022 | Expired |
| US6670384 | Methods of administering epothilone analogs for the treatment of cancer | 23 Jan, 2022 | Expired |
| US7022330 | Parenteral formulation for epothilone analogs | 23 Jan, 2022 | Expired |
| USRE41911 | Epothilone derivatives | 28 Mar, 2021 | Expired |
| USRE41911 | Epothilone derivatives | 28 Sep, 2020 | Expired |
| US7125899 | Epothilone derivatives | 26 Nov, 2018 | Expired |
| US7125899 | Epothilone derivatives | 26 May, 2018 | Expired |
Latest Legal Activities on R-pharm Us Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of R-pharm Us Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jun, 2019 | US7312237 |
|
Email Notification
Critical
| 26 Sep, 2018 | US6670384 |
|
Email Notification
Critical
| 26 Sep, 2018 | US7312237 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Sep, 2018 | US7022330 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Sep, 2018 | US7312237 |
|
Email Notification
Critical
| 26 Sep, 2018 | US7022330 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Sep, 2018 | US6670384 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 26 Sep, 2018 | US7125899 |
|
Correspondence Address Change
Critical
| 25 Sep, 2018 | US6670384 |
|
Correspondence Address Change
Critical
| 25 Sep, 2018 | US7022330 |
|
Correspondence Address Change
Critical
| 25 Sep, 2018 | US7312237 |
|
Correspondence Address Change
Critical
| 25 Sep, 2018 | US7125899 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Apr, 2018 | US7125899 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Oct, 2017 | US7022330 |
| Post Issue Communication - Certificate of Correction | 01 Feb, 2013 | US7125899 |
R-pharm Us Llc's Drug Patent Litigations
R-pharm Us Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 30, 2007, against patent number US7312237. The petitioner , challenged the validity of this patent, with Francis Y.F. Lee as the respondent. Click below to track the latest information on how companies are challenging R-pharm Us Llc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7312237 | January, 2007 |
Decision
(19 Jun, 2007)
| Francis Y.F. Lee | |
R-pharm Us Llc's Family Patents
R-pharm Us Llc Drug List
Given below is the complete list of R-pharm Us Llc's drugs and the patents protecting them.
1. Ixempra Kit
Ixempra Kit is protected by 12 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7312237
(Pediatric)
| Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
21 Feb, 2025
(3 months from now)
| Active |
| US7312237 | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
21 Aug, 2024
(2 months ago)
| Expired |
| USRE41393
(Pediatric)
| Treatment of refractory tumors using epothilone derivatives |
08 Aug, 2022
(2 years ago)
| Expired |
| US6670384
(Pediatric)
| Methods of administering epothilone analogs for the treatment of cancer |
23 Jul, 2022
(2 years ago)
| Expired |
| US7022330
(Pediatric)
| Parenteral formulation for epothilone analogs |
23 Jul, 2022
(2 years ago)
| Expired |
| USRE41393 | Treatment of refractory tumors using epothilone derivatives |
08 Feb, 2022
(2 years ago)
| Expired |
| US6670384 | Methods of administering epothilone analogs for the treatment of cancer |
23 Jan, 2022
(2 years ago)
| Expired |
| US7022330 | Parenteral formulation for epothilone analogs |
23 Jan, 2022
(2 years ago)
| Expired |
| USRE41911
(Pediatric)
| Epothilone derivatives |
28 Mar, 2021
(3 years ago)
| Expired |
| USRE41911 | Epothilone derivatives |
28 Sep, 2020
(4 years ago)
| Expired |
| US7125899
(Pediatric)
| Epothilone derivatives |
26 Nov, 2018
(5 years ago)
| Expired |
| US7125899 | Epothilone derivatives |
26 May, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ixempra Kit's drug page